Price T Rowe Associates Inc. MD Sells 109,051 Shares of Replimune Group, Inc. $REPL

Key Points

• Price T Rowe Associates Inc. MD has reduced its stake in Replimune Group, Inc. by selling **109,051 shares**, now owning approximately **14.09% of the company** valued at **$105.8 million**.
• The stock of Replimune Group has seen a **3.2% decline** recently, with a current market price of **$5.49**, and has a wide 52-week range between **$2.68 and $17.00**.
• Analyst ratings have varied significantly, with **BMO Capital Markets** downgrading the stock to **underperform** with a price target slashed to **$2.00**, while **Cantor Fitzgerald** upgraded it to **overweight**.

Price T Rowe Associates Inc. MD decreased its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 1.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,853,832 shares of the company's stock after selling 109,051 shares during the quarter. Price T Rowe Associates Inc. MD owned approximately 14.09% of Replimune Group worth $105,826,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. American Century Companies Inc. grew its position in shares of Replimune Group by 19.1% during the 1st quarter. American Century Companies Inc. now owns 133,243 shares of the company's stock worth $1,299,000 after buying an additional 21,393 shares in the last quarter. Nuveen LLC bought a new stake in Replimune Group during the first quarter valued at about $6,546,000. Invesco Ltd. boosted its position in Replimune Group by 266.3% during the first quarter. Invesco Ltd. now owns 322,343 shares of the company's stock valued at $3,143,000 after purchasing an additional 234,337 shares in the last quarter. Deutsche Bank AG boosted its position in Replimune Group by 0.4% during the first quarter. Deutsche Bank AG now owns 563,701 shares of the company's stock valued at $5,496,000 after purchasing an additional 2,140 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Replimune Group by 8.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 552,046 shares of the company's stock valued at $5,382,000 after purchasing an additional 43,648 shares in the last quarter. Institutional investors own 92.53% of the company's stock.

Replimune Group Trading Down 3.2%

Shares of NASDAQ:REPL opened at $5.49 on Tuesday. Replimune Group, Inc. has a 52-week low of $2.68 and a 52-week high of $17.00. The stock has a market cap of $428.55 million, a price-to-earnings ratio of -1.69 and a beta of 0.67. The company has a quick ratio of 6.94, a current ratio of 6.94 and a debt-to-equity ratio of 0.21. The business has a 50-day moving average price of $7.70 and a 200-day moving average price of $9.19.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Equities analysts predict that Replimune Group, Inc. will post -2.97 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on REPL. Cantor Fitzgerald raised Replimune Group from a "neutral" rating to an "overweight" rating in a research report on Wednesday, July 30th. BMO Capital Markets downgraded Replimune Group from an "outperform" rating to an "underperform" rating and dropped their price objective for the company from $27.00 to $2.00 in a research report on Wednesday, July 23rd. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $9.00 price objective (down previously from $19.00) on shares of Replimune Group in a research report on Tuesday, July 22nd. Barclays downgraded Replimune Group from an "overweight" rating to an "equal weight" rating and dropped their price objective for the company from $17.00 to $3.00 in a research report on Wednesday, July 23rd. Finally, HC Wainwright downgraded Replimune Group from a "buy" rating to a "neutral" rating in a research report on Wednesday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $7.67.

Insider Activity

In other news, CFO Emily Luisa Hill sold 9,154 shares of the firm's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $5.37, for a total value of $49,156.98. Following the completion of the transaction, the chief financial officer directly owned 134,368 shares in the company, valued at $721,556.16. This trade represents a 6.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 5.20% of the stock is currently owned by insiders.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

Want to see what other hedge funds are holding REPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Replimune Group, Inc. (NASDAQ:REPL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.